Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 14, 2016 08:05 ET | Source: TESARO, Inc.

TESARO Submits New Drug Application for Intravenous Rolapitant to the U.S. Food and Drug Administration

WALTHAM, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has submitted the New Drug Application (NDA)...
February 25, 2016 16:06 ET | Source: TESARO, Inc.

TESARO Announces Fourth-Quarter 2015 Operating Results

U.S. commercial launch of VARUBI® (oral rolapitant) well underwayNiraparib Phase 3 NOVA results expected in Q2 2016 are positioned to be the first data from a randomized, prospective Phase 3 trial...
February 25, 2016 16:05 ET | Source: TESARO, Inc.

TESARO Announces Definitive Agreement for $155 Million Private Placement

WALTHAM, Mass., Feb. 25, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that it has entered into definitive agreements with...
February 11, 2016 08:05 ET | Source: TESARO, Inc.

Tesaro to Announce Fourth Quarter 2015 Financial Results on February 25, 2016

WALTHAM, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its fourth quarter 2015 financial results on Thursday, February 25, 2016, after the close of the U.S....
February 03, 2016 08:05 ET | Source: TESARO, Inc.

TESARO to Present at the Leerink Partners 5th Annual Global Healthcare Conference

WALTHAM, Mass., Feb. 03, 2016 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that Lonnie Moulder, CEO of TESARO, and Mary Lynne Hedley, President and COO of TESARO, will present at...
January 11, 2016 08:15 ET | Source: TESARO, Inc.

TESARO Outlines Business Priorities and Strategic Outlook for 2016

U.S. commercial launch of VARUBI™ (oral rolapitant) well underwayData from niraparib NOVA and QUADRA registration trials expected in Q2 2016 Niraparib New Drug Application (NDA) submission planned...
December 14, 2015 16:05 ET | Source: TESARO, Inc.

TESARO Added to the NASDAQ Biotechnology Index

WALTHAM, Mass., Dec. 14, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Company has been selected for addition to...
November 16, 2015 08:05 ET | Source: TESARO, Inc.

TESARO Announces the Launch of VARUBI(TM) (Rolapitant) in the United States

VARUBI™(rolapitant) provides extended protection for chemotherapy-induced nausea and vomiting (CINV) in the delayed phase (25-120 hours) with a single dose as part of an antiemetic...
November 06, 2015 12:15 ET | Source: TESARO, Inc.

TESARO Announces Data Presentations for Niraparib at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

WALTHAM, Mass., Nov. 6, 2015 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced the presentation of three posters describing niraparib at...
October 29, 2015 16:05 ET | Source: TESARO, Inc.

TESARO Announces Third-Quarter 2015 Operating Results

VARUBI™ (oral rolapitant) approved by U.S. FDA; commercial launch planned for mid-November VARUBI™ added to National Comprehensive Cancer Network (NCCN) Antiemesis Guidelines...